Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02784483 · ClinicalTrials.gov registry record · Phase 1
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02784483 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 2 participants.
The verdict
NCT02784483, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to gain initial insights into the biologic and clinical effects of Atezolizumab in patients with Asymptomatic Multiple Myeloma (AMM). The data may provide novel insights into anti-PDL-1-induced immunologic changes, which could potentially be relevant to its future development in Multiple Myeloma (MM) and other indications.
Interventions
- DRUG Atezolizumab (1200mg via IV infusion)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-02-10 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02784483
The ClinicalTrials.gov registry entry for NCT02784483 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab (1200mg via IV infusion) is the first listed.
NCT02784483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02784483 about?
NCT02784483 is a clinical study titled "Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma". The purpose of this pilot study is to gain initial insights into the biologic and clinical effects of Atezolizumab in patients with Asymptomatic Multiple Myeloma (AMM). The data may provide novel insights into anti-PDL-1-induced immunologic changes, which could potentially be relevant to its future ...
What is the current status of trial NCT02784483?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-02-10. Estimated completion is 2019-04-22.
What interventions are being tested in trial NCT02784483?
The interventions under investigation include: Atezolizumab (1200mg via IV infusion) (DRUG).
Who is sponsoring clinical trial NCT02784483?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.